Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.
Texas Gov. Greg Abbott has asked the federal government to reimburse his state for the more than $11 billion of taxpayer ...